// App-Quantinova.ai

4935 : Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Researchers

Presenter

  • Ghazi Khan

Principal Investigators

  • David A. Rizzieri

  • Joseph O. Moore

  • Jon P. Gockerman

  • Louis F. Diehl

  • Anne W Beaven

  • Donna Adams

  • Julie Warzecho

  • Carlos de Castro

Medical Centers

  • Medicne, Duke University Medical Center, Durham, NC, USA,

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • Circulating tumor cells

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Lenalidomide

  • Decitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved